title: Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients.
abstract: In vitro, Imatinib inhibits the proliferation and stimulates the osteogenic and adipogenic differentiation of mesenchymal stromal cells (MSC). However, it is unknown whether Imatinib affects the biology of MSC in vivo. We asked whether MSC from long-term Imatinib-treated CML patients were affected by the in vivo treatment. MSC from untreated and Imatinib-treated patients displayed normal functional properties (i.e. proliferation, immunophenotype, differentiation and hematopoietic supportive capacity) - but a decreased frequency. In vitro, Imatinib lost its effect when discontinued; which suggest that it has a reversible effect on MSC. Therefore it might lose its effect on MSC after discontinuation in vivo.
authors.affiliation: Niche and Microenvironment Laboratory, Oncology Research Unit, Oncology Hospital, Mexico; Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Coyoacán, México City, Mexico.
authors.forename: P K
authors.initials: PK
authors.lastname: Estrada-González
authors.affiliation: Niche and Microenvironment Laboratory, Oncology Research Unit, Oncology Hospital, Mexico; Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Coyoacán, México City, Mexico.
authors.forename: L
authors.initials: L
authors.lastname: Gómez-Ceja
authors.affiliation: Mesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, Mexico.
authors.forename: J J
authors.initials: JJ
authors.lastname: Montesinos
authors.affiliation: Hematopoietic Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, Mexico.
authors.forename: H
authors.initials: H
authors.lastname: Mayani
authors.affiliation: Leukemic Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Chávez-González
authors.affiliation: Hematology Service, Bernardo Sepulveda Hospital, National Medical Center, IMSS, México City, Mexico.
authors.forename: L
authors.initials: L
authors.lastname: Meillón
authors.affiliation: Hematology Service, Bernardo Sepulveda Hospital, National Medical Center, IMSS, México City, Mexico.
authors.forename: N
authors.initials: N
authors.lastname: Delgado
authors.affiliation: Hematology Service, Bernardo Sepulveda Hospital, National Medical Center, IMSS, México City, Mexico.
authors.forename: E
authors.initials: E
authors.lastname: Sánchez-Nava
authors.affiliation: Niche and Microenvironment Laboratory, Oncology Research Unit, Oncology Hospital, Mexico. Electronic address: eflores.figueroa@gmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Flores-Figueroa
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D002454:Cell Differentiation; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000502:physiology*; D010641:Phenotype; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: Bone remodeling; Chronic myeloid leukemia; Fibrosis; Imatinib; Mesenchymal stromal cells